Publications 2023

Bach-Gansmo T, Hodt A, Schjesvold FH, Gude E, Wien TN (2023)
Bone scintigraphy reduces the need for biopsy in suspected cardiac amyloidosis
Tidsskr Nor Laegeforen, 143 (9)
DOI 10.4045/tidsskr.22.0644, PubMed 37341415

Bogsrud T, Jacobsen M, Durski J, Larsen E, Engelsen O, Haskjold OI, Castillejo M, Bach-Gansmo T, Nostrand DV (2023)
Letter to the Editor: Repeat Redifferentiation of Radioiodine Refractory BRAF^V600E Mutated Thyroid Cancer with Dabrafenib
Thyroid, 33 (6), 771-773
DOI 10.1089/thy.2022.0651, PubMed 37212326

Publications 2022

Bach-Gansmo T, Korsan K, Bogsrud TV (2022)
Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer
Tomography, 8 (3), 1477-1484
DOI 10.3390/tomography8030120, PubMed 35736868

Hoareau R, Bach-Gansmo T, Cumming P, Olberg DE (2022)
A new automated and putatively versatile synthesis of the PSMA-ligand derivative [¹⁸F]DCFPyL using the FASTlab^TM synthesizer
EJNMMI Radiopharm Chem, 7 (1), 10
DOI 10.1186/s41181-022-00157-0, PubMed 35507241

Lindemann M, Oteiza A, Martin-Armas M, Guttormsen Y, Moldes-Anaya A, Berzaghi R, Bogsrud TV, Bach-Gansmo T, Sundset R, Kranz M (2022)
Glioblastoma PET/MRI: kinetic investigation of [¹⁸F]rhPSMA-7.3, [¹⁸F]FET and [¹⁸F]fluciclovine in an orthotopic mouse model of cancer
Eur J Nucl Med Mol Imaging, 50 (4), 1183-1194
DOI 10.1007/s00259-022-06040-z, PubMed 36416908

Publications 2019

Bogsrud TV, Londalen A, Brandal P, Leske H, Panagopoulos I, Borghammer P, Bach-Gansmo T (2019)
18F-Fluciclovine PET/CT in Suspected Residual or Recurrent High-Grade Glioma
Clin Nucl Med, 44 (8), 605-611
DOI 10.1097/RLU.0000000000002641, PubMed 31274605

Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Fendler WP, Czernin J (2019)
What is the best PET target for early biochemical recurrence of prostate cancer?-Authors' reply
Lancet Oncol, 20 (11), e609-e610
DOI 10.1016/S1470-2045(19)30654-0, PubMed 31674314

Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J (2019)
¹⁸F-fluciclovine PET-CT and ⁶⁸Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial
Lancet Oncol, 20 (9), 1286-1294
DOI 10.1016/S1470-2045(19)30415-2, PubMed 31375469

Nanni C, Zanoni L, Bach-Gansmo T, Minn H, Willoch F, Bogsrud TV, Edward EP, Savir-Baruch B, Teoh E, Ingram F, Fanti S, Schuster DM (2019)
[¹⁸F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging-version 1.0
Eur J Nucl Med Mol Imaging, 47 (3), 579-591
DOI 10.1007/s00259-019-04614-y, PubMed 31822959

Publications 2017

Blakkisrud J, Holtedahl JE, Løndalen A, Dahle J, Bach-Gansmo T, Holte H, Nygaard S, Kolstad A, Stokke C (2017)
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate ¹⁷⁷Lu-Lilotomab Satetraxetan
J Nucl Med, 59 (4), 704-710
DOI 10.2967/jnumed.117.195347, PubMed 28848035

Publications 2016

Bach-Gansmo T, Nanni C, Nieh PT, Zanoni L, Bogsrud TV, Sletten H, Korsan KA, Kieboom J, Tade FI, Odewole O, Chau A, Ward P, Goodman MM, Fanti S, Schuster DM, Willoch F (2016)
Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (¹⁸F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer
J Urol, 197 (3 Pt 1), 676-683
DOI 10.1016/j.juro.2016.09.117, PubMed 27746282

Blakkisrud J, Løndalen A, Martinsen AC, Dahle J, Holtedahl JE, Bach-Gansmo T, Holte H, Kolstad A, Stokke C (2016)
Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
J Nucl Med, 58 (1), 48-54
DOI 10.2967/jnumed.116.173922, PubMed 27493270

Munthe E, Riss PJ, Saga TA, Haraldsen I, Grad I, Bogsrud TV, Bach-Gansmo T (2016)
FDG-based quantitative comparison of glucose metabolism in vitro, exemplified by a head-to-head comparison between a triple-negative breast cancer cell line and a non-malignant foetal cell line
Clin Physiol Funct Imaging, 38 (1), 34-37
DOI 10.1111/cpf.12378, PubMed 27297457

Publications 2015

Schulz A, Godt JC, Dormagen JB, Holtedahl JE, Bogsrud TV, Labori KJ, Kløw NE, Bach-Gansmo T (2015)
Respiratory gated PET/CT of the liver: A novel method and its impact on the detection of colorectal liver metastases
Eur J Radiol, 84 (8), 1424-1431
DOI 10.1016/j.ejrad.2015.05.011, PubMed 26044293

Schulz A, Viktil E, Godt JC, Johansen CK, Dormagen JB, Holtedahl JE, Labori KJ, Bach-Gansmo T, Kløw NE (2015)
Diagnostic performance of CT, MRI and PET/CT in patients with suspected colorectal liver metastases: the superiority of MRI
Acta Radiol, 57 (9), 1040-8
DOI 10.1177/0284185115617349, PubMed 26622057

Publications 2014

Bach-Gansmo T, Wien TN, Løndalen A, Halvorsen E (2014)
Myocardial uptake of bone scintigraphic agents associated with increased pulmonary uptake
Clin Physiol Funct Imaging, 36 (3), 237-41
DOI 10.1111/cpf.12219, PubMed 25524030

Schuster DM, Nanni C, Fanti S, Oka S, Okudaira H, Inoue Y, Sörensen J, Owenius R, Choyke P, Turkbey B, Bogsrud TV, Bach-Gansmo T, Halkar RK, Nye JA, Odewole OA, Savir-Baruch B, Goodman MM (2014)
Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease
J Nucl Med, 55 (12), 1986-92
DOI 10.2967/jnumed.114.143628, PubMed 25453047

Publications 2013

Babovic A, Müller C, Bach-Gansmo T (2013)
[When should thyroid scintigraphy be performed?]
Tidsskr Nor Laegeforen, 133 (9), 937
DOI 10.4045/tidsskr.13.0298, PubMed 23652138

Johnsrud K, Skretting A, Naum AG, Bogsrud TV, Bach-Gansmo T (2013)
Characterization of an asymmetric add-on collimator used with a hand-held gamma probe for radioguided surgery and sentinel node detection: a demonstration of an alternative collimation method
Clin Physiol Funct Imaging, 33 (6), 478-82
DOI 10.1111/cpf.12057, PubMed 23758686

Publications 2012

Bach-Gansmo T, Dybvik J, Adamsen T, Naum A (2012)
Variation in urinary excretion of FDG, yet another uncertainty in quantitative PET
Acta Radiol Short Rep, 1 (8)
DOI 10.1258/arsr.2012.120038, PubMed 23986849

Publications 2011

Bach-Gansmo T, Bogsrud TV, Holmboe L, Pedersen EL, Müller C (2011)
Extraosseous uptake with DPD (Teceos(®))
Clin Physiol Funct Imaging, 31 (5), 358-62
DOI 10.1111/j.1475-097X.2011.01024.x, PubMed 21771254

Revheim ME, Røe K, Bruland ØS, Bach-Gansmo T, Skretting A, Seierstad T (2011)
Monitoring the effect of targeted therapies in a gastrointestinal stromal tumor xenograft using a clinical PET/CT
Mol Imaging Biol, 13 (6), 1234-40
DOI 10.1007/s11307-010-0464-0, PubMed 21161686

Publications 2010

Axelsson R, Bach-Gansmo T, Castell-Conesa J, McParland BJ, Study Group (2010)
An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692
Acta Radiol, 51 (1), 40-6
DOI 10.3109/02841850903273974, PubMed 20001475

Bach-Gansmo T, Schwarzlmüller T, Jøraholmen V, Salbu J, Biermann M, Naum A, Kleven-Madsen N (2010)
SPECT/CT hybrid imaging; with which CT?
Contrast Media Mol Imaging, 5 (4), 208-12
DOI 10.1002/cmmi.375, PubMed 20812288

Publications 2009

Bach-Gansmo T, Bogsrud TV (2009)
[Assessment of new medical technology]
Tidsskr Nor Laegeforen, 129 (7), 646
DOI 10.4045/tidsskr.09.33526, PubMed 19337338

Biermann M, Johnsen B, Sørbye H, Følling M, Sundin A, Bach-Gansmo T (2009)
[Positron emission tomography in neuroendocrine tumours]
Tidsskr Nor Laegeforen, 129 (15), 1474-7
DOI 10.4045/tidsskr.08.0068, PubMed 19690598

Revheim ME, Seierstad T, Berner JM, Bruland OS, Røe K, Ohnstad HO, Bjerkehagen B, Bach-Gansmo T (2009)
Establishment and characterization of a human gastrointestinal stromal tumour (GIST) xenograft in athymic nude mice
Anticancer Res, 29 (11), 4331-6
PubMed 20032375

Publications 2008

Bach-Gansmo T, Bogsrud TV, Skretting A (2008)
Integrin scintimammography using a dedicated breast imaging, solid-state gamma-camera and (99m)Tc-labelled NC100692
Clin Physiol Funct Imaging, 28 (4), 235-9
DOI 10.1111/j.1475-097X.2008.00801.x, PubMed 18384623

Publications 2006

Bach-Gansmo T, Danielsson R, Saracco A, Wilczek B, Bogsrud TV, Fangberget A, Tangerud A, Tobin D (2006)
Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692
J Nucl Med, 47 (9), 1434-9
PubMed 16954550

Holte O, Skretting A, Bach-Gansmo T, Hol PK, Johnsrud K, Tønnesen HH, Karlsen J (2006)
Localized internal radiotherapy with 90Y particles embedded in a new thermosetting alginate gel: a feasibility study in pigs
Nucl Med Commun, 27 (2), 185-90
DOI 10.1097/01.mnm.0000194398.97195.d9, PubMed 16404233

Publications 2004

Bach-Gansmo T, Bogsrud TV, Aas M, Jørgensen LH, Fischer BM (2004)
[Positron emission tomography in the diagnosis of lung cancer]
Tidsskr Nor Laegeforen, 124 (8), 1088-9
PubMed 15114384

Publications 2002

Bach-Gansmo T, Bogsrud TV (2002)
[Lung cancer]
Tidsskr Nor Laegeforen, 122 (26), 2559-60; author reply 2560
PubMed 12522888

Publications 2001

Dupas B, Buzelin MF, Karam G, Vasse N, Meflah K, Bach-Gansmo T (2001)
Contrast-enhanced MR imaging of experimental acute tubular necrosis
Acta Radiol, 42 (1), 74-9
DOI 10.1080/028418501127346279, PubMed 11167336

Dupas B, Pradal G, Muller RN, Bonnemain B, Meflah K, Bach-Gansmo T (2001)
Hepatocyte-mediated transport to the bile of AMI-HS, a particulate contrast agent
Invest Radiol, 36 (9), 509-17
DOI 10.1097/00004424-200109000-00002, PubMed 11547038

Publications 1999

Dupas B, Bach-Gansmo T, Blancho G, Franconi JM, Havet T, Léauté F (1999)
Gadolinium-enhanced MR imaging of normal renal transplants. An evaluation of a T1-weighted dynamic echo-planar sequence
Acta Radiol, 40 (3), 250-4
DOI 10.3109/02841859909175550, PubMed 10335961

Publications 1998

Dupas B, Bach-Gansmo T, Meflah K, Muller RN (1998)
Synergistic effects of relaxation and susceptibility in differentiation between compartmentalized and noncompartmentalized tissues
Invest Radiol, 33 (5), 268-72
DOI 10.1097/00004424-199805000-00003, PubMed 9609485

Publications 1997

Dupas B, Bach-Gansmo T, Nomballais MF, Meflah K (1997)
Delineation of liver necrosis using double contrast-enhanced MRI
J Magn Reson Imaging, 7 (3), 472-7
DOI 10.1002/jmri.1880070304, PubMed 9170029

Wang C, Sundin A, Ericsson A, Bach-Gansmo T, Hemmingsson A, Ahlström H (1997)
Dysprosium-enhanced MR imaging for tumor tissue characterization. An experimental study in a human xenograft model
Acta Radiol, 38 (2), 281-6
DOI 10.1080/02841859709172064, PubMed 9093166

Publications 1996

Bach-Gansmo T (1996)
Professional confidentiality is a major right to which our patients are entitled
Acta Radiol, 37 (1), 121
DOI 10.1177/02841851960371P123, PubMed 8611315

Publications 1995

Ericsson A, Bach-Gansmo T, Niklasson F, Hemmingsson A (1995)
Combination of gadolinium and dysprosium chelates as a cellular integrity marker in MR imaging
Acta Radiol, 36 (1), 41-6
PubMed 7833167

Publications 1994

Bach-Gansmo T, Fahlvik AK, Ericsson A, Hemmingsson A (1994)
Superparamagnetic iron oxide for liver imaging. Comparison among three different preparations
Invest Radiol, 29 (3), 339-44
DOI 10.1097/00004424-199403000-00014, PubMed 8175309

Wallengren NO, Holtås S, Andrén-Sandberg A, Bach-Gansmo T (1994)
MR imaging of the pancreas at 0.3 T using a super-paramagnetic oral contrast medium
Acta Radiol, 35 (2), 147-51
PubMed 8172740

Publications 1993

Bach-Gansmo T (1993)
Ferrimagnetic susceptibility contrast agents
Acta Radiol Suppl, 387, 1-30
PubMed 8390776

Bach-Gansmo T (1993)
Ferrimagnetic susceptibility contrast agents
Munksgaard, Copenhagen, 30 s.
BIBSYS 942142284, ISBN 91-628-0871-0

Bach-Gansmo T, Dupas B, Gayet-Delacroix M, Lambrechts M (1993)
Abdominal MRI using a negative contrast agent
Br J Radiol, 66 (785), 420-5
DOI 10.1259/0007-1285-66-785-420, PubMed 8319063

Boudghène FP, Bach-Gansmo T, Grange JD, Lame S, Nantois C, Wallays C, Bigot JM (1993)
Contribution of oral magnetic particles in MR imaging of the abdomen with spin-echo and gradient-echo sequences
J Magn Reson Imaging, 3 (1), 107-12
DOI 10.1002/jmri.1880030118, PubMed 8428075

Oksendal AN, Bach-Gansmo T, Jacobsen TF, Eide H, Andrew E (1993)
Oral magnetic particles. Results from clinical phase II trials in 216 patients
Acta Radiol, 34 (2), 187-93
PubMed 8452728

Publications 1992

Bach-Gansmo T, Ericsson A, Leander P, Fahlvik AK, Hemmingsson A (1992)
Motion associated susceptibility artifacts
Acta Radiol, 33 (6), 606-10
PubMed 1449890

Publications 1991

Ericsson A, Lönnemark M, Hemmingsson A, Bach-Gansmo T (1991)
Effect of superparamagnetic particles in agarose gels. A magnetic resonance imaging study
Acta Radiol, 32 (1), 74-8
PubMed 2012737

Lönnemark M, Hemmingsson A, Bach-Gansmo T, Hagberg H, Magnusson A, Gundersen HG, Nyman R (1991)
Superparamagnetic particles as oral contrast medium in MR imaging of malignant lymphoma
Acta Radiol, 32 (3), 232-8
DOI 10.1177/028418519103200309, PubMed 2064867

Publications 1990

Gundersen HG, Bach-Gansmo T, Holtz E, Fahlvik AK, Berg A (1990)
Superparamagnetic contrast agents for magnetic resonance imaging
Invest Radiol, 25 Suppl 1, S67-8
DOI 10.1097/00004424-199009001-00032, PubMed 2283261

Holtås S, Wallengren NO, Ericsson A, Bach-Gansmo T (1990)
Signal alterations, artifacts and image distortion induced by a superparamagnetic contrast medium. A phantom study in a 0.3 tesla MR system
Acta Radiol, 31 (2), 213-6
PubMed 2372467

Lönnemark M, Hemmingsson A, Ericsson A, Gundersen HG, Bach-Gansmo T (1990)
Oral superparamagnetic particles for magnetic resonance imaging. Effect in plain and viscous aqueous suspensions
Acta Radiol, 31 (3), 303-7
DOI 10.3109/02841859009171997, PubMed 2386643

Niemi P, Katevuo K, Kormano M, Baksaas I, Bach-Gansmo T, Mäenpää J (1990)
Superparamagnetic particles as gastrointestinal contrast agent in magnetic resonance imaging of lower abdomen
Acta Radiol, 31 (4), 409-11
PubMed 2206698

Publications 1989

Lönnemark M, Hemmingsson A, Bach-Gansmo T, Ericsson A, Oksendal A, Nyman R, Moxnes A (1989)
Effect of superparamagnetic particles as oral contrast medium at magnetic resonance imaging. A phase I clinical study
Acta Radiol, 30 (2), 193-6
DOI 10.1177/028418518903000215, PubMed 2923745

Publications 1988

Andrew E, Waaler A, Jakobsen J, Holager T, Lambrechts M, Moxnes A, Kruger Hagen E, Bach-Gansmo T (1988)
Clinical trial program for iopentol. A new nonionic ratio 3.0 contrast medium with emphasis on clinical phases I and II
Invest Radiol, 23 Suppl 1, S189-92
DOI 10.1097/00004424-198809001-00034, PubMed 3058629

Maly P, Bach-Gansmo T, Elmqvist D (1988)
Risk of seizures after myelography: comparison of iohexol and metrizamide
AJNR Am J Neuroradiol, 9 (5), 879-83
PubMed 3140631

Publications 1987

Bach-Gansmo T (1987)
[Contrast media for magnetic resonance tomography]
Tidsskr Nor Laegeforen, 107 (1), 33-6
PubMed 3824287

Valk J, Crezée FC, de Slegte RG, Hazenberg GJ, Wolbers J, Bach-Gansmo T (1987)
Iohexol 300 mg I/ml versus Iopamidol 300 mg I/ml for cervical myelography double blind trial
Neuroradiology, 29 (2), 202-5
DOI 10.1007/BF00327551, PubMed 3295584

Publications 1986

Lilleås F, Bach-Gansmo T, Weber H (1986)
Lumbar myelography with Omnipaque (iohexol)
Neuroradiology, 28 (4), 344-6
DOI 10.1007/BF00333442, PubMed 3762913

Publications 1985

Shaw DD, Bach-Gansmo T, Dahlstrom K (1985)
Iohexol: summary of North American and European clinical trials in adult lumbar, thoracic, and cervical myelography with a new nonionic contrast medium
Invest Radiol, 20 (1 Suppl), S44-50
DOI 10.1097/00004424-198501002-00011, PubMed 3882616

Publications 1984

Nakstad P, Aaserud O, Helgetveit A, Nyberg-Hansen R, Ganes T, Bach-Gansmo T (1984)
Cervical myelography with iohexol
Neuroradiology, 26 (2), 123-9
DOI 10.1007/BF00339860, PubMed 6717790